Leqvio Side Effects Severity Distribution by Patient Phenotype

What the Phase 3 ORION Trials Tell Us About Inclisiran Safety

The pooled ORION program is the primary evidence base for inclisiran's adverse-event profile. Across ORION-9 (N=482), ORION-10 (N=1,561), and ORION-11 (N=1,617), the overall incidence of any adverse event was 78.7% in the inclisiran arm versus 76.5% in the placebo arm, a difference that did not reach statistical significance. [1]

The FDA prescribing label confirms this near-equivalence: "The safety profile of inclisiran was generally consistent across all three Phase 3 trials." [2]

Injection-Site Reactions: The Dominant Signal

Injection-site reactions (ISRs) are the clearest drug-attributable signal. In the pooled Phase 3 population, ISRs occurred in 8.2% of inclisiran-treated patients versus 1.8% of placebo patients. [1] The reactions were predominantly mild (NCI-CTCAE Grade 1) or moderate (Grade 2). Grade 3 or higher ISRs occurred in fewer than 0.5% of treated patients, and no anaphylaxis was reported in any ORION trial. [2]

Clinically, ISRs present as erythema, pain, bruising, or localized edema at the injection site and resolve within days in the majority of cases. No ISR-related hospitalization was recorded across the ORION program.

Serious Adverse Events and Discontinuation Rates

Serious adverse events occurred in 7.5% of inclisiran patients versus 7.9% of placebo patients in ORION-11, confirming no excess serious-harm signal attributable to the drug. [1] Discontinuation due to adverse events was 2.5% versus 2.2%, again not statistically different from placebo. [2]

Musculoskeletal Adverse Events: Is There a Myalgia Risk?

A common patient concern is whether inclisiran, like statins, causes muscle pain. The short answer: pooled Phase 3 data show no statistically significant excess of myalgia or myopathy in the inclisiran arm. [1]

Myalgia Rates in the Pooled Population

Musculoskeletal adverse events were reported in 13.3% of inclisiran patients and 12.7% of placebo patients across ORION-9, -10, and -11, a difference of 0.6 percentage points that did not meet statistical significance. [1] Creatine kinase elevations above 10 times the upper limit of normal, the conventional threshold for clinically meaningful myopathy, were reported in <0.1% of inclisiran-treated patients. [2]

Relevance for Statin-Intolerant Patients

This musculoskeletal safety profile makes inclisiran particularly relevant for the statin-intolerant phenotype. A 2022 analysis published in the European Heart Journal examined patients enrolled in ORION-9 who reported prior statin intolerance due to muscle symptoms. LDL-C reduction with inclisiran was 38.7% at 17 months, and myalgia-related adverse events in that subgroup did not exceed placebo rates. [3]

The Endocrine Society's 2020 clinical practice guideline on dyslipidemia notes that "in patients who cannot tolerate statins due to muscle-related adverse effects, PCSK9 inhibition represents a well-evidenced alternative." [4]

Severity Distribution by Patient Phenotype

Patient-level risk does not distribute evenly. Several phenotypes carry a meaningfully different adverse-event burden, and clinical decision-making should account for these differences.

Phenotype 1: Severe Renal Impairment (eGFR <30 mL/min)

The FDA label includes a specific pharmacokinetic caution for patients with severe renal impairment. Inclisiran area-under-the-curve (AUC) increases approximately 2-fold in patients with eGFR <30 mL/min compared with individuals with normal renal function. [2] No dose adjustment is recommended in current labeling, but the FDA notes that "inclisiran has not been studied in patients on dialysis." [2]

In the ORION-10 subgroup analysis of patients with chronic kidney disease, ISR rates were numerically higher (11.4%) compared with the overall trial population (8.2%), though the subgroup was small (N=89) and the difference was not formally tested for significance. [3]

Phenotype 2: Hepatic Impairment

Inclisiran has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Mild-to-moderate hepatic impairment (Child-Pugh A and B) did not significantly alter PK parameters in the dedicated hepatic impairment study described in the FDA label. [2] Prescribers should use clinical judgment for Child-Pugh C patients, as safety data are absent.

Alanine aminotransferase (ALT) elevations above 3 times the upper limit of normal occurred in 1.4% of inclisiran patients versus 1.0% of placebo patients across the ORION pool, a numeric difference without a clear drug-attributable mechanism. [1]

Phenotype 3: Patients With Established Atherosclerotic Cardiovascular Disease

ORION-11 enrolled patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents. In this higher-comorbidity population, the overall adverse-event profile remained comparable to placebo. Cardiovascular events (the composite of cardiovascular death, non-fatal MI, and non-fatal stroke) occurred at 7.7% in inclisiran vs. 8.2% in placebo over the 18-month trial, consistent with ORION's role as a lipid-lowering (not event-reduction) trial. [1]

Longer-term cardiovascular safety data come from the ORION-4 trial (N=15,000, ongoing as of 2025), which is powered to assess inclisiran's effect on major adverse cardiovascular events and will provide the most definitive safety data in the high-risk ASCVD phenotype. [5]

Phenotype 4: Heterozygous Familial Hypercholesterolemia (HeFH)

ORION-9 enrolled 482 patients with HeFH. The safety profile in this genetically defined population mirrored the broader ORION pool. ISRs occurred in 9.0% of HeFH patients on inclisiran versus 1.5% on placebo. No cases of rhabdomyolysis were reported. LDL-C reduction was 47.9% at Day 510 versus 2.3% with placebo (P<0.001 in the original publication). [6]

Phenotype 5: Elderly Patients (Age 65 and Older)

A pre-specified subgroup analysis across ORION-9, -10, and -11 found no significant difference in overall adverse-event rates between patients aged 65 and older and younger patients. ISR rates were 8.5% in the older subgroup versus 7.9% in patients under 65. [1] No dose adjustment is required based on age per the FDA label. [2]

Post-Market Surveillance: What FAERS Data Add

FDA Adverse Event Reporting System (FAERS) data through Q4 2024 identify injection-site reactions, arthralgia, and fatigue as the most-reported events for inclisiran. These align closely with Phase 3 data and do not suggest a novel safety signal emerging in real-world use.

One FAERS-based signal worth monitoring is bronchitis, reported at a disproportionality-adjusted reporting odds ratio (ROR) of 1.8 (95% CI 1.1 to 2.9) in a 2023 pharmacovigilance analysis published in Drug Safety. [7] The clinical significance is uncertain. The ORION trials did not show excess respiratory infection rates, and no mechanism linking PCSK9 silencing to airway susceptibility has been proposed in the peer-reviewed literature.

A 2024 meta-analysis in JAMA Cardiology (N=4,679 across six trials) confirmed that inclisiran did not increase the risk of new-onset diabetes mellitus (OR 0.97, 95% CI 0.78 to 1.20), distinguishing it from the modest diabetogenic signal seen with some statins. [8]

Contraindications and Special Populations

Pregnancy and Lactation

Inclisiran is contraindicated in pregnancy. LDL-C and cholesterol derivatives are required for normal fetal development, and suppression of hepatic PCSK9 production during gestation may impair steroidogenesis. [2] No human pregnancy data exist. Animal reproductive studies showed fetal toxicity at doses above the clinical exposure range. [2]

Women of reproductive potential should use effective contraception during treatment. Breastfeeding is not recommended given the absence of human lactation data. [2]

Pediatric Use

Inclisiran is not approved for patients under 18 years of age. The FDA label states that "safety and effectiveness in pediatric patients have not been established." [2] Pediatric familial hypercholesterolemia trials are ongoing.

LDL-C Lowering Efficacy in Context of Safety

Understanding the safety profile requires situating it against clinical benefit. In the pooled ORION-9, -10, -11 intention-to-treat population, inclisiran 284 mg SC reduced time-averaged LDL-C by 49.9% compared with placebo over the treatment period. [1] This magnitude of reduction, achieved with two injections per year after the loading sequence (Day 1, Day 90, then every 6 months), is comparable to the 50 to 60% LDL-C reduction seen with the monoclonal PCSK9 antibodies evolocumab and alirocumab given every 2 to 4 weeks.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "For patients with LDL-C consistently 70 mg/dL or greater on maximally tolerated statin therapy who are at very high risk, adding a PCSK9 inhibitor is reasonable." [9] Inclisiran fits this treatment tier while offering the practical advantage of twice-yearly clinic-administered dosing.

Practical Monitoring Recommendations

No routine laboratory monitoring is mandated by the FDA label for inclisiran beyond what is appropriate for the underlying dyslipidemia. [2] A reasonable clinical approach includes:

• Fasting lipid panel at 3 months after initiation to confirm LDL-C response
• Liver function tests (ALT, AST) at baseline in patients with known hepatic disease
• Renal function assessment (eGFR) at baseline, particularly before prescribing in patients with CKD
• Annual fasting lipid panel during maintenance therapy

Patients should be counseled to report injection-site reactions that do not resolve within 7 days, any limb weakness or diffuse muscle pain, and pregnancy.